BR112013021035A2 - composições e métodos de reposição de tecido macio aperfeiçoados - Google Patents

composições e métodos de reposição de tecido macio aperfeiçoados

Info

Publication number
BR112013021035A2
BR112013021035A2 BR112013021035A BR112013021035A BR112013021035A2 BR 112013021035 A2 BR112013021035 A2 BR 112013021035A2 BR 112013021035 A BR112013021035 A BR 112013021035A BR 112013021035 A BR112013021035 A BR 112013021035A BR 112013021035 A2 BR112013021035 A2 BR 112013021035A2
Authority
BR
Brazil
Prior art keywords
methods
soft tissue
tissue replacement
improved soft
replacement compositions
Prior art date
Application number
BR112013021035A
Other languages
English (en)
Inventor
Dennis E Vann Epps
Guang-Liang Jiang
Wha Bin Im
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/193,744 external-priority patent/US8697056B2/en
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112013021035A2 publication Critical patent/BR112013021035A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3666—Epithelial tissues other than skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3869—Epithelial tissues other than skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances

Abstract

composições e métodos de reposição de tecido macio aperfeiçoados o relatório divulga composições e metódos para tratar um defeito de tecido macio de um indivíduo.
BR112013021035A 2011-02-17 2012-02-16 composições e métodos de reposição de tecido macio aperfeiçoados BR112013021035A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161444078P 2011-02-17 2011-02-17
US13/193,744 US8697056B2 (en) 2010-08-19 2011-07-29 Compositions and soft tissue replacement methods
PCT/US2012/025412 WO2012112757A2 (en) 2011-02-17 2012-02-16 Compositions and improved soft tissue replacement methods

Publications (1)

Publication Number Publication Date
BR112013021035A2 true BR112013021035A2 (pt) 2016-10-11

Family

ID=46673171

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013021035A BR112013021035A2 (pt) 2011-02-17 2012-02-16 composições e métodos de reposição de tecido macio aperfeiçoados

Country Status (5)

Country Link
EP (1) EP2675491A2 (pt)
AU (1) AU2012217630A1 (pt)
BR (1) BR112013021035A2 (pt)
CA (1) CA2827615A1 (pt)
WO (1) WO2012112757A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
EP2814510A1 (en) * 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123274A1 (en) * 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
US20230136938A1 (en) * 2020-03-25 2023-05-04 Fukuoka University Agent to be used in intraocular membrane detachment surgery
CN114748682A (zh) * 2022-04-26 2022-07-15 深圳湾实验室 用于制备烧创伤敷料的组合物及其制剂和制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6199076B1 (en) 1996-10-02 2001-03-06 James Logan Audio program player including a dynamic program selection controller
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US20080299213A2 (en) 1999-11-05 2008-12-04 Donald Kleinsek Augmentation and repair of spincter defects with cells including adipocytic cells
WO2001087575A2 (en) 2000-05-12 2001-11-22 The Regents Of The University Of Michigan Reverse fabrication of porous materials
FR2811996B1 (fr) 2000-07-19 2003-08-08 Corneal Ind Reticulation de polysaccharide(s), preparation d'hydrogel(s) ; polysaccharide(s) et hydrogel(s) obtenus,leurs utilisations
AU2002210848A1 (en) 2000-11-27 2002-06-03 Pfizer Products Inc. EP4 receptor selective agonists in the treatment of osteoporosis
DE60239343D1 (de) 2001-07-23 2011-04-14 Ono Pharmaceutical Co Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
US20040254230A1 (en) 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US7651684B2 (en) 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
DK2465537T3 (en) * 2002-10-10 2016-09-19 Ono Pharmaceutical Co MICROSPHERE INCLUDING ONO-1301
US6875787B2 (en) 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
AU2003206922A1 (en) 2003-02-19 2004-09-09 Aventis Pharmaceuticals Holdings Inc. Composition and method for intradermal soft tissue augmentation
EP1613796B1 (en) 2003-04-10 2017-03-22 Tufts University Concentrated aqueous silk fibroin solution and use thereof
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
WO2005032418A2 (en) 2003-10-01 2005-04-14 University Of Washington Novel porous biomaterials
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20080234337A1 (en) 2004-08-10 2008-09-25 Ono Pharmaceutical Co., Ltd. Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
FR2878444B1 (fr) 2004-11-30 2008-04-25 Corneal Ind Soc Par Actions Si Solutions viscoelastiques renfermant du hyaluronate de sodiu et de l'hydroxypropylmethylcellulose, preparation et utilisations
WO2006137472A1 (ja) 2005-06-24 2006-12-28 Taisho Pharmaceutical Co., Ltd. プロスタグランジン誘導体
US20070036844A1 (en) 2005-08-01 2007-02-15 Ma Peter X Porous materials having multi-size geometries
WO2008063569A1 (en) * 2006-11-16 2008-05-29 Coapt Systems, Inc. Co-mixed human fat and gel suspension implant material
WO2008092862A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008092860A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008092861A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008103807A2 (en) 2007-02-21 2008-08-28 Cedars-Sinai Medical Center Methods of producing preadipocytes and increasing the proliferation of adult adipose stem/progenitor cells
CN101686985A (zh) 2007-05-08 2010-03-31 国立大学法人浜松医科大学 含有ep4激动剂的细胞毒性t细胞的活化剂
GB0810615D0 (en) 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
FI20085839A0 (fi) * 2008-09-08 2008-09-08 Timo Ylikomi Menetelmiä ja välineitä pehmytkudosteknologiaan
EP2605762A1 (en) * 2010-08-19 2013-06-26 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition

Also Published As

Publication number Publication date
CA2827615A1 (en) 2012-08-23
EP2675491A2 (en) 2013-12-25
AU2012217630A1 (en) 2013-09-05
WO2012112757A2 (en) 2012-08-23
WO2012112757A3 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
MX2014010455A (es) Metodos y composiciones para tratar enfermedad de huntington.
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
BR112013032229A2 (pt) método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição
CL2012003385A1 (es) Tratamiento para la incontinencia.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
EA201391602A1 (ru) Контролируемое высвобождение иммунодепрессантов из синтетических наноносителей
CR20150047A (es) Anticuerpos anti-cd22 e inmunoconjugados
BR112013022927A2 (pt) composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
UY34559A (es) Inhibidores de bromodominios
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34395A (es) ?Tratamiento de Esclerosis Múltiple con la Combinación de Laquinimod y Fingolimod?.
UY34374A (es) Benzilindazoles sustituidos
UY34210A (es) Composiciones, métodos y sistemas para la micropropagación de plantas
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
BR112012031906A2 (pt) métodos e composições para modular o crescimento de cabelo e pelos.
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
CO7020867A2 (es) Formulaciones de anticuerpo y metodos
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
UY34070A (es) Método y composición para tratamiento de semillas.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]